World Hepatitis Day calls for efforts to eliminate hepatitis by 2030
World Hepatitis Day, marked annually on July 28, seeks to raise awareness and help efforts to end viral hepatitis, a condition marked by liver…
Hepatitis
WHO prequalifies 1st home test for hepatitis C
The World Health Organization (WHO) has prequalified the first self-test kit to detect the hepatitis C virus (HCV) in a home setting, marking…
FDA OKs clinical testing in US of hepatitis D combination treatment
The U.S. Food and Drug Administration (FDA) has approved Vir Biotechnology’s request to conduct clinical testing in the U.S. of a combination of two investigational…
HCV, HIV opt-out testing program to now be evaluated nationwide
A team of researchers, backed by a grant totaling more than $3 million, will study the feasibility of a nationwide opt-out testing program to detect…
Imdusiran plus immunotherapy may help in chronic hepatitis B
In ongoing proof-of-concept Phase 2a trials, Arbutus BioPharma’s imdusiran is showing an ability to possibly eliminate chronic hepatitis B infections when used in…
BJT-778 antibody therapy shows early promise in Hep D trial
Bluejay Therapeutics’ investigational antibody therapy BJT-778 appears to safely and effectively lower levels of the hepatitis D virus (HDV) and markers of liver inflammation…
Tobevibart, elebsiran can suppress hepatitis D virus: Phase 2 data
Vir Biotechnology’s investigational therapy tobevibart, used alone or in combination with another company candidate called elebsiran, can reduce hepatitis D virus (HDV) levels and…
Hepatitis C test-and-treat program works for migrants in Italy: Study
A test-and-treat strategy was effective at identifying and treating hepatitis C among migrants and refugees in Italy coming from low-income countries where the condition…
FDA breakthrough designation granted to larsucosterol for AH
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to larsucosterol, Durect’s investigational therapy for people with severe alcohol-associated hepatitis…
Autoimmune hepatitis treatment zetomipzomib trial seeks patients
A Phase 2a clinical trial testing Kezar Life Sciences’ investigational therapy zetomipzomib in adults with autoimmune hepatitis who did not respond well to standard…
Recent Posts
- Abnormal amino acid profile seen in biliary atresia infants after birth
- Our daughter’s PFIC diagnosis made us rethink drinking at Christmas
- Hepatitis D treatment combo granted new designations in US, EU
- Committee recommends seladelpar approval in EU for treating PBC
- Diet rich in omega-3 fatty acids may lower risk of ICP, scientists say